Medication Considerations

The primary objectives of the SOURCE (Simulation of Opioid Use, Response, Consequences, and Effects) model are threefold: help the FDA and other stakeholders identify high-impact opioid-related interventions, assess potential unanticipated consequences of potential policies, and identify needs for further research.

The Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis.

The FDA Overdose Prevention Framework consists of four overarching priorities that align with the U.S. Department of Health & Human Services' Overdose Prevention Strategy to address the public health emergency as it continues to evolve.

These estimated costs of opioid use disorder and fatal opioid overdose and their per capita costs at the state level can assist federal and state decision makers in understanding the magnitude of opioid use disorder and fatal opioid overdose in their jurisdictions.

This research report provides information on the state of the science in the comorbidity of substance use disorders with mental illness and physical health conditions.

This is an FDA warning that dental problems have been reported with medicines containing buprenorphine that are dissolved in the mouth. Despite these risks, buprenorphine is an important treatment option for opioid use disorder (OUD) and pain, and the benefits of these medicines clearly outweigh the risks.

A Practice Guideline which includes treatment recommendations for patients with substance use disorders, as well as background information and a review of available evidence.

Includes an infographic guide on the benefits of three medications for alcohol use disorder and provides a brief summary of treatment planning and medications approved by the Food and Drug Administration

Reviews the use of disulfiram, acamprosate, and naltrexone for alcohol use disorder (AUD) in primary care, and concludes that the knowledge and prescription of pharmacotherapy for AUD is insufficient

Supplements the CEP's AUD Tool by supporting primary care physicians in screening and managing AUD during the COVID-19 pandemic